Observational study finds biomarkers predict antibody responses to COVID-19 vaccination — Evidence Review
Published in Cell Press Blue, by researchers from Arizona State University
Researched by
— the AI search engine for science
Table of Contents
A recent study suggests that patterns of existing antibodies in the blood can predict how well an individual will respond to a vaccine, even before receiving it. Related research broadly supports the idea that pre-vaccination immune markers are linked to vaccine response, though the specific use of comprehensive antibody profiles as predictors is a novel approach (1, 13).
- Several studies have demonstrated that baseline immune signatures, such as gene expression or specific cell populations, are associated with vaccine responsiveness, supporting the central premise of the new study (1, 2, 13).
- This new research extends previous work by using a wide antibody fingerprint and deep learning, rather than focusing on a single marker or genetic signature, to predict vaccine response, which could be more practical for clinical use (1, 13).
- While prior studies established the importance of post-vaccination antibody titers as correlates of protection (6, 8, 9, 10), the current findings highlight the predictive value of pre-existing antibody patterns, suggesting a potential shift toward personalized vaccination strategies (13).
Study Overview and Key Findings
Understanding why some individuals respond robustly to vaccines while others do not has become increasingly important, especially in the context of infectious diseases like COVID-19. This study, conducted by Arizona State University and published in 2026, investigates whether pre-existing antibodies—reflecting previous immune encounters—can predict the strength of an individual's response to vaccination. The research is notable for its large, diverse cohort and its use of artificial intelligence to analyze a broad spectrum of antibody responses, moving beyond traditional health categories and single biomarkers.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Arizona State University |
| Journal Name | Cell Press Blue |
| Authors | Lusheng Song, Jin G. Park, Ji Qiu, Vel Murugan, Seyedmasoud Mousavi, Ching-Wen Hou, D. Mitchell Magee, Zhongxue Chen, Yunro Chung, Stacy Williams, Deborah Adam, Bihong Guo, Candyce McDaniel, Toria Trendler, Gabe Rice, Kelly Connard, Bradley Bobbett, Michael Ritchie, Izamar Garcia, Guillermo Sebastian Trivino Soto, Giovanna Caruth, Eleni Katergaris, Kristen Seifert, Veronica Boyle, Heewook Lee, Damodara Rao Mendu, Viviana Simon, Komal Srivastava, Bharat Thyagarajan, Mike Ryan, Elena Kowalsky, Patrick Breads, David Fetterer, Troy Kemp, Ann Khalsa, Lora Nordstrom, Michael D. White, Raquel Salgado, Chad M. VanDenBerg, Natacha Montalvo, Craig Woods, Rajat Walia, David Carpentieri, Peter Arden, Christine L. Kuryla, Anay Patel, Lauren Stiene, Imke Folkerts, Stefani N. Thomas, Anne Davidson, Thomas Hickey, Nancy Roche, Ligia Pinto, Norman Kleiman, Carlos Cordon-Cardo, Amy B. Karger, Peter Gregersen, Joshua LaBaer |
| Population | Healthy volunteers and immunosuppressed individuals |
| Sample Size | n=4,089 |
| Methods | Observational Study |
| Outcome | Antibody responses to COVID-19 vaccination |
| Results | Certain biomarkers can predict vaccine response before vaccination. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus research database, which includes over 200 million scientific papers. The following queries were used to identify studies relevant to biomarkers and predictors of vaccine response:
- biomarkers vaccine response prediction
- blood tests vaccine efficacy correlation
- predictive indicators vaccination outcomes
Summary Table of Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How do baseline immune signatures and biomarkers predict vaccine response? | - Baseline immune state, including gene expression and cell populations, is a significant predictor of vaccine response across multiple vaccines (1, 2, 4, 13). - Pre-vaccination pro-inflammatory gene signatures and memory B cell levels are consistently associated with stronger antibody responses (1, 2). |
| Are post-vaccination antibody levels reliable correlates of vaccine-induced protection? | - Post-vaccination antibody titers, particularly neutralizing and binding antibodies, are strongly correlated with vaccine efficacy and protection against infection (6, 8, 9, 10). - These immune markers are used to establish correlates of protection for COVID-19 and other vaccines (6, 8, 9, 10). |
| Can clinical or demographic factors alone predict vaccine response variability? | - Factors such as age, underlying health conditions, and immune status impact vaccine responsiveness, but do not fully explain individual variation (2, 11, 13). - Some immunosuppressed or healthy individuals show unexpected vaccine responses, suggesting a need for more precise predictors (2, 11). |
| What is the potential for personalized or precision vaccination strategies? | - Integrating baseline immune biomarkers could enable tailored vaccine schedules or interventions to optimize outcomes (1, 13). - There is growing support for using pre-vaccination immune profiles to individualize vaccine recommendations (1, 13). |
How do baseline immune signatures and biomarkers predict vaccine response?
A recurring theme in vaccine research is the predictive power of pre-vaccination immune markers, such as gene expression profiles or memory B cell populations. The new study's use of broad antibody fingerprints aligns with previous findings that baseline immune characteristics can forecast the magnitude of vaccine-induced antibody responses (1, 2, 4, 13). This approach may offer a more accessible clinical tool compared to gene expression assays.
- Pre-vaccination immune signatures, including pro-inflammatory gene expression, have been linked to stronger vaccine responses across diverse vaccines (1).
- Levels of switched memory B cells and activation-induced cytidine deaminase (AID) activity before vaccination also predict the strength of the antibody response (2).
- Machine learning models using multiple immune variables, including apoptosis markers, can predict vaccine responsiveness with high accuracy (4).
- The new study builds on these insights by employing a comprehensive antibody profile and AI to predict vaccine response, broadening the range of potential biomarkers (13).
Are post-vaccination antibody levels reliable correlates of vaccine-induced protection?
While the new study focuses on pre-vaccination predictors, a substantial body of research demonstrates that antibody titers measured after vaccination are reliable correlates of protection. These findings have supported the use of antibody levels as surrogate markers in vaccine development and approval (6, 8, 9, 10).
- Neutralizing and binding antibody titers post-vaccination are strongly associated with reduced risk of symptomatic and severe COVID-19 and other infections (6, 8, 9, 10).
- These correlates are used to estimate vaccine efficacy and guide public health recommendations (8, 10).
- While post-vaccination titers are well-established, the new study's focus on pre-vaccination predictors represents a complementary approach that could inform vaccination strategies before administration.
Can clinical or demographic factors alone predict vaccine response variability?
Clinical and demographic factors such as age, underlying health status, and immune suppression are known to influence vaccine responses, but they do not account for all observed variability (2, 11, 13). The new study highlights that even among healthy individuals, some exhibit weak responses, indicating the need for more individualized predictors.
- Age-related declines in memory B cell populations and immune function contribute to weaker vaccine responses, but not all elderly individuals respond poorly (2).
- Iron deficiency and anemia at the time of vaccination can decrease vaccine response, suggesting modifiable factors beyond demographic characteristics (11).
- The new study's findings support the notion that antibody fingerprints may provide additional predictive value beyond traditional clinical risk factors (13).
What is the potential for personalized or precision vaccination strategies?
The integration of baseline immune profiling into vaccine planning could transform vaccination from a one-size-fits-all approach to a more tailored strategy (1, 13). The new research supports the feasibility of using pre-vaccination antibody patterns to guide clinical decisions.
- Personalized vaccination could involve identifying individuals likely to have weak responses and offering them additional doses or alternative vaccines (1, 13).
- Baseline immune signatures offer potential targets for interventions aimed at boosting vaccine responsiveness prior to immunization (13).
- The current study demonstrates a practical method—antibody profiling—that may be easier to implement than gene expression-based assays (1, 13).
Future Research Questions
Despite advances in understanding vaccine response prediction, important questions remain. Further research is needed to validate the predictive power of antibody fingerprints across different vaccines, explore underlying mechanisms, and determine how best to integrate these biomarkers into clinical practice.
| Research Question | Relevance |
|---|---|
| Do pre-vaccination antibody profiles predict responses to vaccines other than COVID-19? | Determining whether the predictive value of antibody fingerprints extends to other vaccines is necessary for broader clinical application (1, 13). |
| What mechanisms underlie the association between pre-existing antibodies and vaccine responsiveness? | Understanding the biological pathways connecting pre-existing antibodies and immune readiness could reveal new targets for enhancing vaccine efficacy (1, 13). |
| Can AI-based antibody fingerprint models be integrated into routine clinical practice? | Assessing the feasibility, cost-effectiveness, and accuracy of implementing these models in healthcare settings is essential for translation to patient care (1). |
| How do demographic and clinical factors interact with antibody profiles to influence vaccine response? | Investigating these interactions may help identify subgroups who could benefit most from tailored vaccination strategies (2, 11, 13). |
| What interventions can improve vaccine response in individuals predicted to be weak responders? | Exploring interventions, such as supplemental doses or immune modulation, could translate predictive insights into improved health outcomes (11, 13). |